271 related articles for article (PubMed ID: 24362693)
1. Respiratory syncytial virus disease: prevention and treatment.
Chu HY; Englund JA
Curr Top Microbiol Immunol; 2013; 372():235-58. PubMed ID: 24362693
[TBL] [Abstract][Full Text] [Related]
2. Respiratory syncytial virus fusion nanoparticle vaccine immune responses target multiple neutralizing epitopes that contribute to protection against wild-type and palivizumab-resistant mutant virus challenge.
Gilbert BE; Patel N; Lu H; Liu Y; Guebre-Xabier M; Piedra PA; Glenn G; Ellingsworth L; Smith G
Vaccine; 2018 Dec; 36(52):8069-8078. PubMed ID: 30389195
[TBL] [Abstract][Full Text] [Related]
3. [Respiratory syncytial virus].
Tsutsumi H
Uirusu; 2005 Jun; 55(1):77-84. PubMed ID: 16308533
[TBL] [Abstract][Full Text] [Related]
4. Respiratory syncytial virus-neutralizing monoclonal antibodies motavizumab and palivizumab inhibit fusion.
Huang K; Incognito L; Cheng X; Ulbrandt ND; Wu H
J Virol; 2010 Aug; 84(16):8132-40. PubMed ID: 20519399
[TBL] [Abstract][Full Text] [Related]
5. Targeting RSV with vaccines and small molecule drugs.
Costello HM; Ray WC; Chaiwatpongsakorn S; Peeples ME
Infect Disord Drug Targets; 2012 Apr; 12(2):110-28. PubMed ID: 22335496
[TBL] [Abstract][Full Text] [Related]
6. Respiratory syncytial virus entry inhibitors targeting the F protein.
Sun Z; Pan Y; Jiang S; Lu L
Viruses; 2013 Jan; 5(1):211-25. PubMed ID: 23325327
[TBL] [Abstract][Full Text] [Related]
7. Palivizumab for immunoprophylaxis of respiratory syncytial virus (RSV) bronchiolitis in high-risk infants and young children: a systematic review and additional economic modelling of subgroup analyses.
Wang D; Bayliss S; Meads C
Health Technol Assess; 2011 Jan; 15(5):iii-iv, 1-124. PubMed ID: 21281564
[TBL] [Abstract][Full Text] [Related]
8. Respiratory syncytial virus: prospects for new and emerging therapeutics.
Jorquera PA; Tripp RA
Expert Rev Respir Med; 2017 Aug; 11(8):609-615. PubMed ID: 28574729
[TBL] [Abstract][Full Text] [Related]
9. Updated guidance for palivizumab prophylaxis among infants and young children at increased risk of hospitalization for respiratory syncytial virus infection.
;
Pediatrics; 2014 Aug; 134(2):415-20. PubMed ID: 25070315
[TBL] [Abstract][Full Text] [Related]
10. Respiratory syncytial virus prefusogenic fusion (F) protein nanoparticle vaccine: Structure, antigenic profile, immunogenicity, and protection.
Patel N; Massare MJ; Tian JH; Guebre-Xabier M; Lu H; Zhou H; Maynard E; Scott D; Ellingsworth L; Glenn G; Smith G
Vaccine; 2019 Sep; 37(41):6112-6124. PubMed ID: 31416644
[TBL] [Abstract][Full Text] [Related]
11. Compassionate use experience with high-titer respiratory syncytical virus (RSV) immunoglobulin in RSV-infected immunocompromised persons.
Falsey AR; Koval C; DeVincenzo JP; Walsh EE
Transpl Infect Dis; 2017 Apr; 19(2):. PubMed ID: 28054734
[TBL] [Abstract][Full Text] [Related]
12. New strategies for control of respiratory syncytial virus infection.
Nokes JD; Cane PA
Curr Opin Infect Dis; 2008 Dec; 21(6):639-43. PubMed ID: 18978532
[TBL] [Abstract][Full Text] [Related]
13. Hyper-Enriched Anti-RSV Immunoglobulins Nasally Administered: A Promising Approach for Respiratory Syncytial Virus Prophylaxis.
Jacque E; Chottin C; Laubreton D; Nogre M; Ferret C; de Marcos S; Baptista L; Drajac C; Mondon P; De Romeuf C; Rameix-Welti MA; Eléouët JF; Chtourou S; Riffault S; Perret G; Descamps D
Front Immunol; 2021; 12():683902. PubMed ID: 34163482
[TBL] [Abstract][Full Text] [Related]
14. Palivizumab: where to from here?
Georgescu G; Chemaly RF
Expert Opin Biol Ther; 2009 Jan; 9(1):139-47. PubMed ID: 19063700
[TBL] [Abstract][Full Text] [Related]
15. Intravenous palivizumab and ribavirin combination for respiratory syncytial virus disease in high-risk pediatric patients.
Chávez-Bueno S; Mejías A; Merryman RA; Ahmad N; Jafri HS; Ramilo O
Pediatr Infect Dis J; 2007 Dec; 26(12):1089-93. PubMed ID: 18043443
[TBL] [Abstract][Full Text] [Related]
16. Generation and Characterization of ALX-0171, a Potent Novel Therapeutic Nanobody for the Treatment of Respiratory Syncytial Virus Infection.
Detalle L; Stohr T; Palomo C; Piedra PA; Gilbert BE; Mas V; Millar A; Power UF; Stortelers C; Allosery K; Melero JA; Depla E
Antimicrob Agents Chemother; 2016 Jan; 60(1):6-13. PubMed ID: 26438495
[TBL] [Abstract][Full Text] [Related]
17. Palivizumab and the prevention of respiratory syncytial virus illness in pediatric patients with congenital heart disease.
Feltes TF; Sondheimer HM
Expert Opin Biol Ther; 2007 Sep; 7(9):1471-80. PubMed ID: 17727335
[TBL] [Abstract][Full Text] [Related]
18. GS-5806 Inhibits a Broad Range of Respiratory Syncytial Virus Clinical Isolates by Blocking the Virus-Cell Fusion Process.
Perron M; Stray K; Kinkade A; Theodore D; Lee G; Eisenberg E; Sangi M; Gilbert BE; Jordan R; Piedra PA; Toms GL; Mackman R; Cihlar T
Antimicrob Agents Chemother; 2015 Dec; 60(3):1264-73. PubMed ID: 26666922
[TBL] [Abstract][Full Text] [Related]
19. Respiratory syncytial virus: from pathogenesis to potential therapeutic strategies.
Shang Z; Tan S; Ma D
Int J Biol Sci; 2021; 17(14):4073-4091. PubMed ID: 34671221
[TBL] [Abstract][Full Text] [Related]
20. Comparison of Palivizumab-Like Antibody Binding to Different Conformations of the RSV F Protein in RSV-Infected Adult Hematopoietic Cell Transplant Recipients.
Ye X; Iwuchukwu OP; Avadhanula V; Aideyan LO; McBride TJ; Ferlic-Stark LL; Patel KD; Piedra FA; Shah DP; Chemaly RF; Piedra PA
J Infect Dis; 2018 Mar; 217(8):1247-1256. PubMed ID: 29365155
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
